Seelos Therapeutics, Inc. (SEEL) News
Filter SEEL News Items
SEEL News Results
|Loading, please wait...|
SEEL News Highlights
- For SEEL, its 30 day story count is now at 5.
- Over the past 21 days, the trend for SEEL's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- ATAI, CMPS and MNMD are the most mentioned tickers in articles about SEEL.
Latest SEEL News From Around the Web
Below are the latest news stories about Seelos Therapeutics Inc that investors may wish to consider to help them evaluate SEEL as an investment opportunity.
GAINERS: Seelos Therapeutics (NASDAQ: SEEL ) shares closed up 11.06% at $1.10 Mind Medicine (NASDAQ: MNMD ) shares closed up 11.01% at $1.21 Compass Pathways (NASDAQ: CMPS ) shares closed up 4.50% at $13.23 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 3.83% at $5.42 Mindset Pharma (OTC: Full story available on Benzinga.com
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Seelos Therapeutics (SEEL – Research Report) today and set a price target of $6.00. The company's shares closed last Wednesday at $1.20, close to its 52-week low of $1.00. According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -19.6% and a 28.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. Seelos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
GAINERS: Small Pharma (OTC: Full story available on Benzinga.com
GAINERS: Small Pharma (OTC: DMTTF ) shares closed up 14.55% at $0.21 GH Research (NASDAQ: GHRS ) shares closed up 3.35% at $16.99 Field Trip Health (NASDAQ: FTRP ) shares closed up 2.00% at $2.04 LOSERS: Mindset Pharma (OTC: MSSTF ) shares closed down -4.33% at $0.57 Seelos Therapeutics (NASDAQ: SEEL ) shares closed down Full story available on Benzinga.com
Brokerages forecast that Seelos Therapeutics, Inc. (NASDAQ:SEEL) will report earnings per share of ($0.12) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Seelos Therapeutics earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.12). Seelos Therapeutics posted earnings per share of ($0.13) during the same 
Brokerages expect Seelos Therapeutics, Inc. (NASDAQ:SEEL) to report earnings per share (EPS) of ($0.12) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Seelos Therapeutics earnings. The lowest EPS estimate is ($0.12) and the highest is ($0.11). Seelos Therapeutics reported earnings of ($0.13) per share during the same quarter 
NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 11th Annual LifeSci Partners Corporate Access Event, January 5-7th, 2022.
The trading price of Seelos Therapeutics Inc. (NASDAQ:SEEL) closed lower on Monday, December 13, closing at $1.70, -1.73% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy
No summary available.